DXM Abuse Prevention Act of 2017
- Last Action
- 3/17/2017
Actions
- 2017-03-17Referred to the Subcommittee on Health.
- 2017-03-01Referred to the House Committee on Energy and Commerce.
- 2017-03-01Introduced in House
- 2017-03-01Introduced in House
CRS Summary
As of 2017-03-01 (00)
DXM Abuse Prevention Act of 2017
This bill amends the Federal Food, Drug, and Cosmetic Act to: (1) require a retailer that sells certain drugs containing dextromethorphan (DXM) to have a verification system that is intended to ensure that no one under 18 years of age purchases such drugs from the retailer, (2) establish other restrictions on the sale of over-the-counter drugs containing DXM, and (3) establish restrictions on the distribution of bulk DXM.
Cosponsors (6)
- Doris Matsui (D-CA)
- Patrick Meehan (R-PA)
- RON KIND (D-WI)
- ALCEE HASTINGS (D-FL)
- Paul Tonko (D-NY)
- Yvette Clarke (D-NY)
Subjects
- Child health
- Civil actions and liability
- Drug safety, medical device, and laboratory regulation
- Drug trafficking and controlled substances
- Drug, alcohol, tobacco use
- Licensing and registrations
- Prescription drugs
- Retail and wholesale trades
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.